Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection Milestone marks Eyconis’ transition to a clinical-stage biotechnology company REDWOOD CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) — Eyconis, Inc., a biotechnology company developing next-generation, long-acting ophthalmic therapeutics, […]